Reglagene is developing novel, orally administered medicines designed to fight life threatening brain cancers known as high-grade glioma. Early testing has shown promise in delivering well-tolerated treatment that can cross the blood-brain barrier to deliver effective treatment that may improve patient prospects.
www.reglagene.com
MILESTONESSeries A |
TARGET CANCERSHigh-Grade Glioma (Brain Cancer) |
FOCUS SECTORTherapies & Management |
WHY WE INVESTED
We love Reglagene’s global impact potential as a cost-effective disruptor to the brain cancer space. Only four of the 217 FDA-approved cancer medicines are indicated for life-threatening brain cancers. The main reason for the lack of innovation in brain cancer treatment is the extreme difficulty of cancer medicines crossing the blood-brain barrier, a filter that protects the brain from toxins. Reglagene’s lead therapeutic compound is ripe for changing the treatment paradigm for brain cancer patients – it crosses the blood-brain barrier, is orally administered, and is well-tolerated in high doses.
